Volume 3 Issue 1
Review Article: Cladribine in First Line and Relapsed Hairy Cell Leukemia and the Hairy Cell Leukemia Variant
Marlies Van Hoef1* and Xavier Troussard2
Hairy cell leukemia is a rare disease for which purine nucleoside analogues changed disease outcome. Pentostatin and 2-chorodeoxyadenosine (cladribine) have meanwhile been administered since over two decades. The former compound is available for intravenous administration and the latter for both intravenous and subcutaneous administration. Cladribine induces high response rates in first line purine nucleoside analog treatment, regardless of prior treatment with splenectomy, interferon or chemotherapy, and is also effective in relapsed disease. Literature describing the use of cladribine upfront and in later lines of treatment in hairy cell leukemia and the hairy cell leukemia variant is reviewed herein.
Keywords: Hairy cell leukemia (variant); Cladribine; Rituximab; First line; Relapsed
Cite this Article: Van Hoef M, Troussard X. Cladribine in First Line and Relapsed Hairy Cell Leukemia and the Hairy Cell Leukemia Variant. Int J Blood Dis Dis. 2019; 3(1): 001-007.
Published: 02 January 2019
Authors submit all Proposals and manuscripts via Electronic Form!